Biology Direct Immunology

Mesenchymal stem cell-mediated mitochondrial transfer: from intercellular communication to precision mitochondrial therapy

Zhou, Zhou, Li, Wen, Fang, Jiankai, Melino, Gerry, Shi, Yufang, Cao, Lijuan
Springer Nature · 2026-11-20 · DOI 10.1186/s13062-026-01072-z

Abstract

Mesenchymal stem cells (MSCs) have emerged as promising therapeutic agents in regenerative medicine, with their therapeutic effects increasingly attributed to intercellular communication and microenvironmental regulation rather than long-term engraftment or direct tissue replacement. Among these mechanisms, mitochondrial transfer represents a form of organelle-mediated intercellular communication through which cells exchange intact mitochondria or mitochondria-associated cargo. MSCs are prominent candidate donors because of their responsiveness to injury-associated cues, paracrine and immunomodulatory properties, and regulated mitochondrial trafficking. However, mitochondrial transfer is not unique to MSCs, may be bidirectional or multidirectional, and is not invariably beneficial; its consequences depend on donor and recipient states and may range from physiological homeostasis and tissue repair to maladaptive responses. In this review, we summarize the molecular mechanisms underlying MSC-mediated mitochondrial transfer, with particular emphasis on injury sensing, tunneling nanotube (TNT)-mediated trafficking, extracellular vesicle (EV)-associated delivery, recipient-cell selectivity, and mitochondrial quality control. We compare major transfer routes, including TNTs, EV-associated delivery, uptake of extracellular or isolated mitochondria, and cell fusion, highlighting their mechanistic features and evidentiary limitations. We further discuss how transferred mitochondria and mitochondrial-associated cargos regulate cellular bioenergetics, redox homeostasis, and immunometabolic states, and evaluate their therapeutic implications across diverse disease contexts, including tissue injury, inflammatory disorders, and metabolic dysfunction. We also examine the extent to which current evidence distinguishes the contribution of mitochondrial transfer from the broader therapeutic effects of MSCs, particularly paracrine signaling and immunomodulation. Finally, we discuss strategies for enhancing transfer efficiency, establishing mitochondrial quality and potency criteria, developing precision delivery platforms, and addressing the major biosafety and manufacturing challenges that must be overcome for clinical translation.

Read at publisher →